愈肝龙胶囊联合恩替卡韦治疗慢性乙型肝炎肝纤维化30例

Effect of Yuganlong Capsule Combined with Entecavir in Treatment of 30 Cases of Patients with Chronic Hepatitis B Cirrhosis

目的观察愈肝龙胶囊联合恩替卡韦治疗慢性乙型肝炎肝纤维化的临床疗效。方法将57例慢性乙型肝炎肝硬化患者随机分为治疗组30例和对照组27例,对照组给予恩替卡韦,治疗组给予愈肝龙胶囊联合恩替卡韦。观察两组患者治疗前和治疗96周后Fibroscan肝硬度值,血清肝纤维四项(HA、LN、C-Ⅳ、PC-Ⅲ),肝功能指标(ALT、AST、GGT、TBi L),超声影像学指标(门脉内径、脾脏厚度)。结果治疗前两组各项指标均差异无统计学意义(P>0.05);治疗96周后,治疗组Fibroscan值、肝纤维化指标(HA、LN、C-Ⅳ),ALT,AST较治疗前显著降低(P<0.05),且与对照组治疗后比较,差异有统计学意义(P<0.05)。结论愈肝龙胶囊联合恩替卡韦治疗慢性乙型肝炎肝纤维化效果优于单用恩替卡韦。

Objective To observe the clinical efficacy of Yuganlong capsule combined with entecavir in treatment of liver fibrosis in patients with chronic hepatitis B cirrhosis.Methods A total of 57 cases of patients with chronic hepatitis B cirrhosis were randomly divided into treatment group（30 cases given entecavir） and control group（27 cases treated with Yuganlong capsule combined with entecavir）.Fibroscan values,hepatic fibrosis indexes（HA,LN,C-Ⅳ,PC-Ⅲ）,liver function index（ALT,AST,GGT,T-BiL）,and ultrasonic imaging index（inner diameters of portal vein,thickness of spleen） were detected.Results Before treatment,all indicatorshad no significant differences between the two groups（ P 〉0.05）.After 96 weeks of treatment,the Fibroscan value,HA,LN,C-Ⅳ,ALT,AST and portal vein diameter were significantly reduced in the treatment group as compared with those before treatment（all P 〈0.05）,and there were significant differences between the treatment group and the control group after the treatment（all P 〈0.05）. Conclusion The effect of Yuganlong capsule combined with entecavir in the treatment of chronic hepatitis B liver cirrhosis is better than that of using entecavir alone to improve liver function and liver fibrosis.